Kiora Pharmaceuticals INC Schedule 13G passive stakes

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have filed a corrected Schedule 13G to accurately report their beneficial ownership of Kiora Pharmaceuticals, Inc. common stock.

Nantahala Capital Management, LLC and its principals have reported a 9.99% beneficial ownership stake in Kiora Pharmaceuticals, Inc. as of March 31, 2026.

Alyeska Investment Group, L.P. has filed a Schedule 13G reporting beneficial ownership of 9.99% of Kiora Pharmaceuticals, Inc. common stock through warrant holdings.

Nantahala Capital Partners Limited Partnership has filed an amendment reporting beneficial ownership of 3.388% of Kiora Pharmaceuticals, Inc. common stock.

Rosalind Advisors and affiliated entities report a 9.9% potential beneficial ownership in Kiora Pharmaceuticals Inc. through warrants, subject to a blocker provision.

AIGH Capital Management and Orin Hirschman disclose a 4.9% beneficial ownership stake in Kiora Pharmaceuticals, Inc. as of December 31, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Kiora Pharmaceuticals, Inc. as of September 30, 2025.

ADAR1 Capital Management, its general partner, and Daniel Schneeberger collectively report a 9.9% beneficial ownership stake in Kiora Pharmaceuticals, Inc. as of June 30, 2025.

Nantahala Capital Partners Limited Partnership has disclosed a 5.299% beneficial ownership stake in Kiora Pharmaceuticals, Inc., including shares acquirable via warrants.

Rosalind Advisors and related entities disclose potential beneficial ownership of 9.9% of Kiora Pharmaceuticals common shares via warrants, currently unexercisable due to a blocker provision.

Alyeska Investment Group, L.P. and its affiliates reported a beneficial ownership of 2.5% of Kiora Pharmaceuticals, Inc.'s common stock as of December 31, 2024, through warrants.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amended Schedule 13G, confirming a passive beneficial ownership of 130 shares, representing 0.0% of Kiora Pharmaceuticals, Inc.'s common stock as of December 31, 2024.

Rosalind Advisors, Inc., Steven Salamon, Gilad Aharon, and Rosalind Master Fund L.P. have filed an amended Schedule 13G, disclosing a potential beneficial ownership of 9.9% in Kiora Pharmaceuticals Inc., though actual exercisable shares are limited by a blocker provision.

AIGH Capital Management LLC and Orin Hirschman have jointly reported a beneficial ownership of 8.5% in Kiora Pharmaceuticals, Inc. common stock as of December 31, 2024.